



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>3</sup> :</b> <b>A61L 17/00, 15/04; A61F 1/00</b> <b>C08L 67/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 84/ 00 30</b> <b>(43) International Publication Date:</b> 2 February 1984 (02.02.84)
<b>(21) International Application Number:</b> PCT/NL83/00027 <b>(22) International Filing Date:</b> 15 July 1983 (15.07.83) <b>(31) Priority Application Number:</b> 8202893 <b>(32) Priority Date:</b> 16 July 1982 (16.07.82) <b>(33) Priority Country:</b> NL  <b>(71) Applicant (for all designated States except US):</b> RIJK-SUNIVERSITEIT TE GRONINGEN [NL/NL]; Broerstraat 5, NL-9712 CP Groningen (NL).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> GOGOLEWSKI, Sylvester [PL/NL]; Oostersingel 59, NL-9713 EZ Groningen (NL). PENNING, Albert, Johan [NL/NL]; Ettenlaan 3, NL-9331 BE Norg (NL). WILDEVUUR, Charles, Roelf, Hendrik [NL/NL]; Ossenmarkt 8, NL-9712 NZ Groningen (NL).  <b>(74) Agent:</b> URBANUS, H., M.; Vereenigde Octrooibureaux, Nieuwe Parklaan 107, NL-2587 BP The Hague (NL).		<b>(81) Designated States:</b> AU, BE (European patent), BR C (European patent), DE (European patent), DK F (European patent), FR (European patent), GB (European patent), JP L (European patent), NL (European patent), NO S (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> BIOCOMPATIBLE, ANTITHROMBOGENIC MATERIALS SUITABLE FOR RECONSTRUCTIVE SURGERY  <b>(57) Abstract</b>  Biocompatible, highly antithrombogenic material for reconstructive surgery, which is based on poly(L-lactic acid) and/or poly(DL-lactic acid) and segmented polyester urethanes or polyether urethanes.		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	LI	Liechtenstein
AU	Australia	LK	Sri Lanka
BE	Belgium	LU	Luxembourg
BR	Brazil	MC	Monaco
CF	Central African Republic	MG	Madagascar
CG	Congo	MR	Mauritania
CH	Switzerland	MW	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SE	Sweden
FR	France	SN	Senegal
GA	Gabon	SU	Soviet Union
GB	United Kingdom	TD	Chad
HU	Hungary	TG	Togo
JP	Japan	US	United States of America
KP	Democratic People's Republic of Korea		

Title: Biocompatible, antithrombogenic materials suitable for reconstructive surgery.

The invention relates to a new biocompatible, highly antithrombogenic material, of adjustable porosity, compliance and biodegradability, based on polylactic acid and segmented polyurethanes, for reconstructive surgery, which can be built up in layers with  
5 different compositions and characteristics and can be modelled in various shapes by including reinforcement material. The versatility of the material, according to the present invention gives it a unique adaptability to the biological tissue in which it is incorporated, so that the synthetic material is built up into a new functional entity  
10 in reconstructive surgery.

Most synthetic materials used for reconstruction do not have the same mechanical properties as the specific biological tissue and so do not match its specific function. It is known that the specific function of tissue is the trigger of the constant rebuilding  
15 of tissue in the growth during life. The variability of the elastic properties of the material according to the present invention renders it possible to match the mechanical properties of most of the biological tissue that has to be replaced in the body.

As its porosity can be varied, the ingrowth and overgrowth  
20 of tissue for complete incorporation can be regulated to provide optimum conditions for a specific replacement. Its adjustable biodegradability makes it possible, if desired, to have the synthetic material completely replaced by biological tissue.

Because of the possibility to produce the material in layers  
25 of different compositions, it is also possible to have the characteristics of each layer match the function of the biological tissue needed to rebuild that layer.

Because the material can be modelled by the shapes of mandrels by a dipping technique, every form can be produced to match the shape  
30 of an organ to be replaced, such as a tubular neo-artery for example. But also a more complex organ such as a trachea can be produced from

this synthetic material, including a reinforcement material in the layers to maintain its shape during the alternating positive and negative pressures occurring in the trachea and to prevent collapsing. The constructive reinforcement material can be made of a different material, for example porous hydroxy apatite, which could induce bone formation.

Due to the biodegradability and high flexibility of the polylactide-polyurethane porous membranes, these materials can also be used to cover satisfactorily large experimental full-thickness skin wounds. Such membranes can effectively protect these wounds from infection and fluid loss for a long time.

Thus these combinations give a wide range of new possibilities in reconstructive surgery, all based on the same principle that perfect matching of the mechanical properties of biological tissue and synthetic materials creates one functional unity between biological tissue and the synthetic material which allows complete incorporation and rebuilding to a new organ. This new composition has been tested in animal experiments, primarily with rabbits, as vascular and tracheal prostheses and artificial skin. In these experiments true biocompatibility and a high degree of antithrombogenicity of the material was demonstrated. The experiments with the tracheal prosthesis revealed that quick tissue ingrowth from the peritracheal tissue is induced if relatively large pores (100  $\mu$ ) were used on the outside. However, overgrowth of tissue on the luminal side needed only a thin connective tissue layer to which epithelium became firmly attached and differentiated. This was achieved with relatively small pores on the inside (10 - 20  $\mu$ ). Between the layers of various pore sizes a reinforcement of a spiral bead may be embedded.

This possibility of variation by means of different layers can also be used for the composition of an artificial skin where such functions as controlled evaporation, ingrowth of tissue, seeding of epithelial cells and resistance to outside micro-organism require layers with different characteristics.

More specifically the invention relates to the provision of a material which comprises the following composition in wt. %:  
poly(L-lactic acid) and/or poly(DL-lactic acid) with a viscosity-average



molecular weight in the range of  $2 \times 10^5$  to  $5 \times 10^6$ , from 5 to 95; and polyester urethane or polyether urethane, from 5 to 95.

Polyester urethane or polyether urethane may be based on:

5 polytetramethylene adipate, poly(ethyleneglycol adipate), poly(tetramethylene oxide), poly(tetramethylene glycol) or poly(diethyleneglycol adipate, p,p'-diphenylmethane diisocyanate, or toluene diisocyanate, or hexamethylene diisocyanate and 1,4 butanediol or ethylene diamine.

The segmented polyurethane imparts the desired flexibility, strength and antithrombogenicity to the material.

10 The polylactic acid ensures the required modulus and porosity. By varying the proportion of polylactic acid, the proposed compliance and type or porosity can be controlled. As the ester, ether and urethane groups of polyurethane and the carboxylic group of polylactic acid exhibit poor hydrolytic stability, the material easily breaks down to be  
15 eliminated from the body after replacement of the graft by the body tissues.

In order to increase the rate of material resorption in the body, it is recommended to use a material which contains at least 20 % by weight of polylactic acid and polyester urethane, based on  
20 hexamethylene diisocyanate, polyethyleneglycol adipate and 1,4-butanediol.

In order to improve antithrombogenic effect, the polyurethane based on polytetramethylene glycol and p,p'-diphenylmethane may be used.

For the preparation of arteries, arteriovenous shunts or cardiopulmonary bypass, the following compositions of the material, in  
25 % by weight, are recommended:

- a. poly(L-lactic acid) or poly(dL-lactic acid), 20;  
polyether urethane, 80.
- b. polylactic acid, 30;  
polyether urethane, 70.
- 30 c. polylactic acid, 15;  
polyether urethane, 85.

For the preparation of veins with a diameter in the range of 1,5 to 10 mm, the following composition, in % by weight, is recommended:

- a. polylactic acid, 80;  
35 polyester urethane, 20.
- b. polylactic acid, 70;



- polyester urethane, 30.  
c. polylactic acid, 60;  
polyester urethane, 40.

For the preparation of tracheal prostheses with a diameter  
5 in the range of 7 - 25 mm, the following composition, in % by weight,  
is recommended:

- a. polylactic acid, 50;  
polyester or polyeter urethane, 50.  
b. polylactic acid, 40;  
10 polyester of polyeter urethane, 60.

For the preparation of artificial skin having a size in the  
range of 50 to 500 mm by 50 to 500 mm the following composition, in  
% by weight, is recommended:  
15 polylactic acid, 20 to 50;  
polyester urethane 50 to 80.

The techniques applied for the preparation of tubular grafts  
and porous membranes may for example be as follows:

A. Vascular grafts

- a) For higher concentrations of polylactic acid in the mixture:  
20 Polylactic acid is dissolved in chloroform at room temperature and 5 to  
20 % by weight of sodium citrate in chloroform ethanol mixture is added  
to the solution. Polyurethane is dissolved in tetrahydrofuran so as to  
give a solution with a concentration in the range of 5 - 15 % by weight.

The solutions of polylactic acid and polyurethane are mixed  
25 together right before the preparation of the tubes.

The tubes are prepared on a stainless steel mandrel coated  
with polytetrafluoroethylene. For this purpose the mandrels are dipped  
into the polymer solution and dried at room temperature. Dipping and  
solvent evaporation procedure is repeated to provide the graft with a  
30 required wall thickness. The grafts are extracted with distilled water  
and ethanol for 5 to 10 hours to remove sodium citrate.

Depending on the concentration of sodium citrate in the  
polymer solution and the proportion of polylactic acid, the size of the  
pores formed in the grafts is in the range of 5 to 200  $\mu$ m. In addition  
35 the pore size may be adjusted by changing the polymer concentration in  
the solution from which the grafts are made. From a more concentrated  
solution grafts with smaller pores are obtained. When layers of polymer

are deposited on the mandrel from solutions with different polymer concentrations composite grafts are formed having a gradually increasing pore size, suitable for certain types of implants.

b) For higher concentrations of polyurethane in the mixture:

- 5 Poly(lactic acid) is dissolved in tetrahydrofuran at 50 to 90°C. Polyurethane is dissolved separately in tetrahydrofuran. The two solutions are mixed together prior to the graft preparation. The concentration of polymer in the solution is in the range of 5-20 % by weight.

10 Tubes are prepared on stainless steel mandrels coated with polytetrafluoroethylene (PTFE), the mandrels being dipped into the polymer solution maintained at a temperature of 60 to 85°C and next into an ethanol distilled water mixture to precipitate the polymer.

Depending on the concentration of polymer in the solution, a porous structure with different pore size is formed. The structure  
15 is composed of thin, elastic polyurethane fibers covered with a thin layer of poly(lactic acid).

As a general rule it is recommended that more concentrated polymer solutions are used for the preparation of grafts having smaller pore sizes.

- 20 These highly porous poly(lactic acid) - polyurethane materials composed of randomly distributed holes and elastic fibers exhibit both radial and linear compliance.

In all cases the pore-to-matrix ratio by volume can be adjusted from 0 to 90 percent.

25 B. Tracheal Prostheses

Solutions of polymers were prepared as described in Aa and Ab.

- After the deposition of 2 to 3 polymer layers on the mandrel, a reinforcing bead extruded from polyether urethane or polyamide urethane is wound tightly around the polymer-coated mandrel and another coating  
30 of polymer is applied. Due to partial dissolution and swelling of the surface of the reinforcing bead, an excellent, homogenous connection between the bead and the inner and outer walls of the prostheses is formed.

C. Artificial skin

- 35 Solutions of polymers are prepared as described in Aa and Ab. A glass cylinder with a rough, sand-blasted surface is dipped into

the polymer solution maintained at a temperature of 60 to 85°C, and next into an ethanol distilled water mixture to precipitate the polymer.

After washing with water and extraction with ethanol the porous sleeve is removed from the glass mould and cut along its longitudinal axis.

On the upper side of the membrane a polyether urethane or Dow Corning Silastic Medical Adhesive Type A is spread.

The diameter and the length of the glass mold may be in the range of 50 to 200 mm and 50 to 200 mm, respectively, depending on the size of the piece of artificial skin required for implantation.

The proposed material in the form of vascular and tracheal grafts and porous membranes-artificio with various polylactic acid-polyurethane compositions and porosities, was tested in vivo for anticlotting properties and tissue ingrowth by implanting into chincilla rabbits and albino rats weighing 2 to 2.5 kg and 100 to 150 g, respectively.

Histological analysis showed no clotting, connective tissue ingrowth, blood vessels ingrowth, etc.





C L A I M S

1. Biocompatible, highly antithrombogenic material for reconstructive surgery, which is based on poly(L-lactic acid) and/or poly(dL-lactic acid) and segmented polyester urethanes or polyether urethanes.
- 5 2. Material according to claim 1, characterized by the following composition in % by weight:  
poly(L-lactic acid), 5 to 95,  
or  
poly(dL-lactic acid), 5 to 95, and  
10 polyester urethane, 5 to 95,  
or  
polyether urethane, 5 to 95.
3. Material according to claims 1-2, characterized in that the polyester urethane is based on:  
15 poly(tetramethylene adipate), poly(ethyleneglycol adipate), p,p'-diphenylmethane diisocyanate, toluene diisocyanate, hexamethylene diisocyanate, and 1,4-butanediol or ethylene diamine; and the polyether urethane is based on:  
poly(tetramethylene oxide), poly(tetramethylene glycol), poly-  
20 (diethyleneglycol adipate), p,p'-diphenylmethane diisocyanate, toluene diisocyanate, hexamethylene diisocyanate, and 1,4-butanediol, or ethylene diamine.
4. Biocompatible, highly antithrombogenic, biodegradable grafts based on polylactic acid and segmented polyurethanes, characterized in  
25 that compliance is adjusted by the ratio between the polylactic acid and the polyurethane in the mixture.
5. Biocompatible highly antithrombogenic, biodegradable grafts based on polylactic acid and segmented polyurethanes, characterized in that the pore size and the pore-to-matrix ratio by volume is adjusted  
30 from 0 to 90 percent.



# INTERNATIONAL SEARCH REPORT

International Application No. **PCT/NL 83/00027**

## I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC<sup>3</sup>: A 61 L 17/00; A 61 L 15/04; A 61 F 1/00; C 08 L 67/04

## II. FIELDS SEARCHED

Minimum Documentation Searched \*

Classification System

Classification Symbols

IPC<sup>3</sup>

A 61 L 17/00; D 01 F 6/92; C 08 L 67/04

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are included in the Fields Searched \*

## III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>14</sup>

Category *	Citation of Document, <sup>15</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>
A	FR, A, 1478694 (ETHICON) 28 April 1967 see page 6, lines 33-54 --	1
A	FR, A, 2088548 (ETHICON) 7 January 1972 see page 14, lines 1-9 --	1
A	FR, A, 2401185 (ETHICON) 23 March 1979 --	
A	FR, A, 2267748 (AMERICAN CYANAMID) 14 November 1975 --	
A	FR, A, 2440380 (F.E. GOULD) 30 May 1980 --	
A	FR, A, 1461386 (DU PONT) 9 December 1966 see abstract 2e -----	1

\* Special categories of cited documents: <sup>16</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Δ" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search \*

10th October 1983

Date of Mailing of this International Search Report \*

14 NOV. 1983

International Searching Authority <sup>1</sup>

EUROPEAN PATENT OFFICE

Signature of Authorized Officer <sup>19</sup>

G.L.M. Kruidenberg

# ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO.

PCT/NL 83/00027 (SA 5479)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 02/11/83

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A- 1478694		NL-A- 6605197	21/10/66
		BE-A- 679726	19/10/66
		DE-A- 1642111	30/12/71
		CH-A- 526963	31/08/72
		GB-A- 1123445	
		SE-B- 353021	22/01/73
FR-A- 2088548	07/01/72	NL-A- 7103263	16/11/71
		DE-A- 2062604	25/11/71
		US-A- 3636956	25/01/72
		US-A- 3797499	19/03/74
		BE-A- 758156	28/04/71
		CA-A- 982007	20/01/76
		CH-A- 573752	31/03/76
		SE-B- 361599	12/11/73
FR-A- 2401185	23/03/79	DE-A- 2827289	11/01/79
		US-A- 4137921	06/02/79
		US-A- 4157437	05/06/79
		GB-A- 1595269	12/08/81
		CA-A- 1124444	25/05/82
FR-A- 2267748	14/11/75	US-A- 3896802	29/07/75
		NL-A- 7504655	21/10/75
		BE-A- 828133	20/10/75
		DE-A- 2515865	30/10/75
		AU-A- 7899875	16/09/76
		GB-A- 1476894	16/06/77
		AT-B- 342214	28/03/78
		JP-A- 50146181	22/11/75
		AU-B- 498891	29/03/79
		CA-A- 1059853	07/08/79
		CH-A- 614123	15/11/79
		SE-A- 7504547	23/12/75
		SE-B- 411298	17/12/79
		US-A- 3903882	09/09/75
		CA-A- 1066579	20/11/79
FR-A- 2440380	30/05/80	DE-A- 2827450	11/01/79
		US-A- 4156066	22/05/79

For more details about this annex :

see Official Journal of the European Patent Office, No. 12/82

INTERNATIONAL APPLICATION NO.  
-----PCT/AL 83/00027 (SA 5479)  
-----

US-A-	4156067	22/05/79
JP-A-	54010398	25/01/79
GB-A-	1605079	16/12/81
GB-A-	1605080	16/12/81

-----  
FR-A- 1461386None  
-----

---

For more details about this annex :  
see Official Journal of the European Patent Office, No. 12/82